NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is effective in EGFR T790M positive non-small-cell lung cancer (NSCLC). Despite the efficacy of osimertinib, patients inevitably develop resistance and the mechanisms of osimertinib resistance ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan, Yang, DaFu, Cui, SaiQiong, Pan, Evenki, Yang, Peng, Dai, ZhaoXia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312323/
https://www.ncbi.nlm.nih.gov/pubmed/34321891
http://dx.doi.org/10.2147/OTT.S318250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312323/
https://www.ncbi.nlm.nih.gov/pubmed/34321891
http://dx.doi.org/10.2147/OTT.S318250

Ejemplares similares